Skip to content

STEMLINE THERAPEUTICS INC: 10-Q filed 2016-11-08

What STEMLINE THERAPEUTICS INC reported in its quarterly report filed 2016-11-08 (fiscal Q3 2016): 25 published measures, 72 facts as tagged in accession 0001104659-16-155564.

This filing

Form
10-Q (quarterly report)
Filed
2016-11-08
Fiscal period
fiscal Q3 2016
Accession
0001104659-16-155564 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All STEMLINE THERAPEUTICS INC filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2016-09-3075,081,172USD
At 2015-12-3198,215,623USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2016-09-309,275,544USD
At 2015-12-3110,103,667USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2016-09-3065,805,628USD
At 2015-12-3188,111,956USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2016-09-309,127,991USD
At 2015-12-3113,376,196USD
At 2015-09-3021,286,572USD
At 2014-12-3125,007,217USD

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2016-09-30-125,733,511USD
At 2015-12-31-97,439,602USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2016-07-01 to 2016-09-30-8,822USD92
2016-01-01 to 2016-09-30-35,578USD274

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2016-09-3023,482USD
At 2015-12-3195,661USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2016-01-01 to 2016-09-305,710,071USD274
2015-01-01 to 2015-09-304,484,815USD273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2016-07-01 to 2016-09-30-10,065,428USD92
2016-01-01 to 2016-09-30-28,758,336USD274
2015-07-01 to 2015-09-30-9,370,199USD92
2015-01-01 to 2015-09-30-27,324,928USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2016-09-3051,026,740USD
At 2015-12-3146,691,330USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2016-09-309,115,569USD
At 2015-12-319,455,477USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2016-07-01 to 2016-09-3010,364,829USD92
2016-01-01 to 2016-09-3029,500,289USD274
2015-07-01 to 2015-09-309,575,850USD92
2015-01-01 to 2015-09-3027,773,437USD273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2016-07-01 to 2016-09-307,176,960USD92
2016-01-01 to 2016-09-3020,585,659USD274
2015-07-01 to 2015-09-307,340,859USD92
2015-01-01 to 2015-09-3021,575,743USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2016-09-3019,151,652shares
At 2015-12-3118,235,020shares

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2016-09-30-47,512USD
At 2016-06-30-35,159USD
At 2015-12-31-153,690USD
At 2015-09-3035,615USD
At 2015-06-3014,061USD
At 2014-12-313,000USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2016-09-30463,104USD
At 2015-12-31383,797USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2016-09-30212,305USD

Other noncurrent liabilities

Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2016-09-30159,975USD
At 2015-12-3131,241USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2016-09-30523,612USD
At 2015-12-31651,889USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2016-07-01 to 2016-09-30-9,932,044USD92
2016-01-01 to 2016-09-30-28,329,487USD274
2015-07-01 to 2015-09-30-9,233,076USD92
2015-01-01 to 2015-09-30-27,064,255USD273

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2016-07-01 to 2016-09-30-9,935,575USD92
2016-01-01 to 2016-09-30-28,187,731USD274
2015-07-01 to 2015-09-30-9,211,522USD92
2015-01-01 to 2015-09-30-27,031,640USD273

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2016-07-01 to 2016-09-30-9,923,222USD92
2016-01-01 to 2016-09-30-28,293,909USD274
2015-07-01 to 2015-09-30-9,233,076USD92
2015-01-01 to 2015-09-30-27,064,255USD273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2016-07-01 to 2016-09-303,187,869USD92
2016-01-01 to 2016-09-308,914,630USD274
2015-07-01 to 2015-09-302,234,991USD92
2015-01-01 to 2015-09-306,197,694USD273

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2016-07-01 to 2016-09-30952USD92
2016-01-01 to 2016-09-3079,306USD274
2015-07-01 to 2015-09-3038,333USD92
2015-01-01 to 2015-09-30115,000USD273

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2016-01-01 to 2016-09-3059,954USD274
2015-01-01 to 2015-09-3064,106,372USD273
2015-01-01 to 2015-03-3164,100,000USD90

Inspect the source

Entity
STEMLINE THERAPEUTICS INC / CIK 0001264587
Captured
SEC response SHA-256
4bc563f579ac3611fca3a4b0f91dded31bf19c0e78ed6a10086fa540610de496

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001264587.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))